Why ‘female Viagra’ isn’t approved in the UK – and what to try instead
The term 'female viagra' doesn't refer to an elusive or much-wished-for drug – it really exists. Its brand name is Addyi, but ...
Medscape6d
EMA Recommends Approval of Capvaxive Pneumococcal Vaccine
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
Medscape6d
EMA Expedites Adolescent Chikungunya Vaccine Recommendation
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
ophthalmologytimes2d
CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars
The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...
GlobalData on MSN21h
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
FiercePharma6d
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Pharmaceutical Technology on MSN2d
AstraZeneca lung cancer therapy Imfinzi recommended for EU approval
EMA's CHMP has recommended AstraZeneca's Imfinzi for approval in the EU as a single agent for limited-stage small cell lung ...
PMLiVE3d
J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
AstraZeneca, Daiichi win EU backing for breast cancer drug Dato-DXd
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
Pharmabiz2d
Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%
Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...